Biotechnology

CEL-SCI

CEL-SCI released FY2025 9 Months earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -6.9458

CEL-SCI released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -1.3647

CEL-SCI Completes $5.7 Million Market Offering

CEL-SCI Partners with Saudi Pharma Firm to Advance Multikine

CEL-SCI Announces $5.7 Million Market Stock Offering

CEL-SCI Files for Up to $100 Million Shelf Offering

FDA Paves Accelerated Approval Path for CEL-SCI's Multikine Immunotherapy

CEL-SCI Announces Public Offering To Raise $5 Million

CEL-SCI's Multikine Drug Awaits Breakthrough Designation

CEL-SCI released FY2025 Q2 earnings on May 14 (EST) with actual revenue of USD 0 and EPS of USD -2.3325

CEL-SCI released FY2025 Semi-Annual Earnings on May 14 (EST), with actual revenue of USD 0 and EPS of USD -5.4713

CEL-SCI Corporation Seeks Early Approval for Multikine in Head and Neck Cancer Treatment

CEL-SCI Corporation Reports MULTIKINE Treatment Improves Quality of Life for Head and Neck Cancer Patients by 95%

CEL-SCI released FY2025 Q1 earnings on February 14 (EST), actual revenue USD 0, actual EPS USD -3.2485

CEL-SCI released FY2024 annual earnings on January 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -15.3109 (forecast USD -17.7017)

CEL-SCI released FY2024 Q4 earnings on January 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.9688 (forecast USD -3.3003)

CEL-SCI Reaches Agreement with FDA for Head and Neck Cancer Market Registration Study

CEL-SCI Corporation to Present New Data on Multikine Study at ESMO 2024

CEL-SCI released FY2024 9 Months earnings on August 14 EST, actual revenue USD 0, actual EPS USD -12.5087

CEL-SCI released FY2024 Q3 earnings on August 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.1764 (forecast USD -3.9003)

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap